- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
International Journal of Alzheimer's Disease
Volume 2012 (2012), Article ID 604141, 10 pages
Reliable Measurements of the β-Amyloid Pool in Blood Could Help in the Early Diagnosis of AD
1Araclon Biotech Ltd., I + D Laboratory, Zaragoza, Spain
2Araclon Biotech Ltd., Proteomic Laboratory, CIBIR Logroño, Spain
3Alzheimer Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurciències Aplicades, Barcelona, Spain
Received 13 December 2011; Revised 7 May 2012; Accepted 9 May 2012
Academic Editor: Seishi Terada
Copyright © 2012 Pedro Pesini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The present study was aimed at assessing the capability of Aβ1-40 and Aβ1-42 levels in undiluted plasma (UP), diluted plasma (DP), and cell bound (CB) to distinguish between early stages of Alzheimer's disease (AD), amnesic mild cognitive impairment (MCI), and healthy control (HC). Four blood samples from each participant were collected during one month and the levels of Aβ1-40 and Aβ1-42 were determined by a blinded proprietary ELISA sandwich (Araclon Biotech. Zaragoza, Spain). First striking result was that the amount of Aβ1-40 and Aβ1-42 in UP represented only a small proportion () of the total beta-amyloid pool in blood (βAPB) described here as the sum of Aβ1-40 and Aβ1-42 in blood where they are free in plasma, bound to plasma proteins, and bound to blood cells. Furthermore, we found that levels of Aβ1-40 and Aβ1-42 in UP, DP, and CB were significantly higher in MCI when compared to HC. On average, the total βAPB was 1.8 times higher in MCI than in HC () and allowed to discriminate between MCI and HC with a sensitivity and specificity over 80%. Thus, quantification of several markers of the βAPB could be useful and reliable in the discrimination between MCI and HC.
Histopathological hallmarks of AD are senile plaques and neurofibrillary tangles. It is becoming increasingly clear that development of these lesions appears to take place over a period of many years before any measurable cognitive impairment can be detected . Thus, there is an urgent need for biomarker-based tests that allow a more accurate and early diagnosis of the disease. Such tests should improve the monitoring of the disease progression, enable early therapeutic intervention (before irreversible neurodegeneration has taken place), allow a better selection of AD cohorts for clinical trials, and serve for the evaluation of new AD therapies, particularly amyloid targeting drugs and vaccines .
Recently it has been shown that CSF levels of Aβ1-42, total tau, and phosphorylated-tau proteins define a biomarker signature that is diagnostic for AD and appears to predict conversion from MCI to AD [2–6]. Indirectly, these results reinforce the idea that Aβ blood levels could also have diagnostic significance, although the relationship among brain, CSF, and plasma peptide levels in health and disease is complex and far from being thoroughly understood [7–9].
The practical advantages of a blood test over a CSF test are clear and do not need to be stressed. However, until now attempts to measure Aβ peptides in blood have produced contradictory and discouraging results, mostly for a variety of technical reasons that certainly compromise but, in our opinion, do not invalidate the working hypothesis [10–12]. Indeed, it is well established that Aβ blood levels are elevated before the onset of dementia in dominant-inherited early AD and Downs syndrome [13, 14]. Levels of Aβ peptides have also been found to be elevated in healthy elderly people before late-onset AD and in people with high risk of developing AD, such as women with MCI and first-degree relatives of patients with late-onset AD [15–17]. Furthermore, it has been recently shown that higher plasma levels of Aβ1-42 in healthy people are associated with increased risk of developing AD in the follow-up period [16, 18, 19]. Interestingly, several studies suggest that conversion to AD is followed by a significant decline in plasma Aβ peptide levels after the onset of dementia and with progression of symptoms [15, 16, 19–21]. The consensus arising from these papers is congruent with studies in an AD mouse model (tg 2576), which have shown highly significant decreases in plasma Aβ1-40 and Aβ1-42 linked to the marked accumulation of Aβ in the brain that begins in these animals at 6–9 months of age .
Regarding Aβ blood tests, it is also important to take into account that due to the biochemical nature of Aβ peptides, particularly their extreme hydrophobicity, they will be found free in the plasma, bound to plasma proteins, and bound to blood cells [23–25]. Thus, any Aβ blood test should consider the amount of peptides in each of these three fractions, which we have described collectively as the β-amyloid pool in blood (βAPB); a concept that certainly will evolve because it is known that apart from Aβ1-40 and Aβ1-42, other Aβ species are present in blood and experimental results suggest that they could play a role in the disease and may also be of value in the diagnosis .
The present work is aimed at exploring whether measurements of the different fractions of the βAPB could provide reliable and useful biomarkers for MCI and early AD stages.
2. Material and Methods
2.1. Study Population
The study included 40 participants: 16 healthy controls (HC), 8 amnesic mild cognitive impairment patients (MCI), and 16 Alzheimer’s disease patients (AD). All were over 65 years of age and each group comprised 50% male and 50% female. Demographic characteristics of the participants are summarized in Table 1.
Healthy controls were carefully selected from community-dwelling, socially active volunteers (no blood-relatives to the patients) with an absence of memory complaints, normal performance in neuropsychological tests, and absence of structural alterations in quantitative magnetic resonance imaging (MRI).
Participants with MCI fulfilled the Mayo Clinic criteria. Additional requirements for the selection of MCI participants included a clinical dementia ratio (CDR) of 0.5 points, more than 3 points on the Scheltens scale for medial temporal atrophy (MTA)  and a pattern of parietal and/or temporal hypometabolism in positron emission tomography with 18-fluorodeoxyglucose (PET-FDG) suggestive of AD. Patients with any psychiatric or systemic pathology, other than possible neurodegenerative disease, that could cause the MCI were excluded. Specific inclusion criteria for the AD group were a diagnosis of probable AD (NINCDS-ADRDA criteria), a CDR of 1 point, a mini-mental state examination (MMSE) between 16 and 24 points, and more than 3 points on the Scheltens scale for medial temporal atrophy.
Cognitive testing for HC, MCI, and AD diagnosis was performed according to the routines of the Memory Clinic of Fundació ACE as described elsewhere .
Written informed consent was obtained from every participant or their closest relative in the case of several AD patients. The study protocols were reviewed and approved by the Ethical Committee of the Hospital Clinic i Provincial (Barcelona, Spain).
2.2. Blood Sampling and Biochemical Determinations
Four blood samples (BS1 to BS4) per participant were obtained in the morning after an overnight fast for four consecutive weeks. Blood samples were collected in polypropylene vials with EDTA and protease inhibitor cocktail (Complete Mini, Roche); they were immediately centrifuged, aliquoted, and coded without any reference to the cognitive state of the participant. Two independent 5 mL blood samples from each participant were collected for ApoE genotyping and clinical blood analysis including cell-hemogram. The aliquots of plasma and the remaining cell pellet were immediately frozen at −80°C and sent to the Araclon laboratory. APOE genotyping was performed by amplification of genomic DNA, digestion with HhaI, and analysis of the restriction fragments . Aβ1-40 and Aβ1-42 were measured in plasma and cell fractions using two specific ELISA sandwich kits, ABtest 40 and ABtest 42 (Araclon Biotech, Zaragoza, Spain). Before analysis, plasma and blood cell samples were pretreated by 1 : 3 dilution in a formulated sample buffer (PBS 0.5 M, 0.5% Tween-20, 1% blocking polymer) according to the supplier’s instructions. An anti-Aβ N-terminal monoclonal antibodies was used as capture antibody and two highly specific anti C-terminal polyclonal antibody, pAB002 and pAB031 (Araclon Biotech, Zaragoza, Spain), were used as detection antibody for Aβ1-40 and Aβ1-42, respectively. Thus, levels of Aβ1-40 and Aβ1-42 were separately determined in undiluted plasma (UP), diluted plasma (DP) and cell bound (CB) fractions. Briefly, samples were incubated overnight with capture antibody at 4°–8°C without shaking. Subsequent incubations (1 hour each) were performed at room temperature gently shaking the plates in an orbital 3D platform and were followed by 5 minutes washing. During last incubation with the chromogen, the absorbance was read at 620 nm until it reached 0.60–0.65. Then, the reaction is stopped and the absorbance read at 450 nm for interpolation in the standard curve. Subsequently, aliquots of sixteen randomly chosen samples from any extraction and participant were sent to two clinical diagnostic laboratories for the evaluation of inter-laboratory reproducibility of the measurements. Assays were independently performed following the ABtest 40 and ABtest 42 data sheets by separate personnel and equipment. Samples and peptide standards were always assayed in triplicate.
2.3. Statistic Analysis
Interlaboratory reproducibility of the measurements was assessed by the concordance correlation coefficient (CCC) which evaluates the agreement among the three readings from the same sample, our own, and those reported by the two external laboratories, measuring the deviation of the reading from the 45° line through the origin (the concordance line). This is written Rc = R × Cb. The term R is the standard Pearson correlation coefficient, while Cb (bias correction factor) = 2/( + + ) where and = /SQRT( × ; , and , being the mean and standard deviation of the first and second set of measurements in each comparison . Intrasubject reproducibility along the four blood samples was assessed by the intra-class correlation coefficient (ICC). The degree of agreement estimated by these correlation coefficients was described as poor (0.21 to 0.40), moderate (0.41 to 0.60), substantial (0.61 to 0.80), or almost perfect (0.81 to 1.00). The Aβ levels in the different diagnostic groups were compared using the Mann-Whitney test. The categorical variables (education level and ApoE4 genotype) were compared by Chi-square test. Spearmans analysis was used to evaluate correlations among continuous variables. was required for rejection of the null hypothesis. All statistical analysis, including receiver operating characteristic (ROC) curve analysis, was performed with SAS 9.1 software. Graphs in Figures 1–2 were generated with SigmaPlot 11.0 software. Lack of normality, linearity and homoscedasticity in the distribution of the Aβ marker values prevented the statistical comparisons between groups to be reliably adjusted for the age of the participants.
3.1. Inter- and Intralaboratory Reproducibility of Aβ Measurements
Sixteen randomly chosen samples from any participant and blood sampling were sent to two external laboratories for the evaluation of interlaboratory reproducibility of the measurements. The six markers directly assayed in the samples (Aβ1-40 and Aβ1-42 for UP, DP, and CB) behaved in a similar way with a CCC that ranged from 0.84 to 0.99 (overall 95% CI from 0.73 to 0.99) which corresponds to a degree of agreement between substantial to almost perfect in all cases (complementary material, Table 2).
Average intra-assay reproducibility, expressed as the coefficient of variation of the triplicate wells, for the six markers in each laboratory was 4.31, 5.83, and 8.34 (complementary material, Table 3). The lower limit of detection (LLD) of the assays in the three laboratories was 5.31, 3.63, and 1.91 pg/mL for Aβ1-40 and 2.37, 2.04, and 2.45 pg/mL for Aβ1-42.
3.2. Intra-Individual Reproducibility of Aβ Measurements
The reproducibility of Aβ measurements among the four weekly blood collections (BS1–BS4) as measured by the ICC varied between substantial to almost perfect for all the direct markers in the three groups (complementary material, Table 4). Generally, for the three diagnostic groups, the higher ICC corresponded to the measurements of Aβ1-40 and Aβ1-42 in DP; these were 0.93 (95% CI = 0.98–0.80) and 0.93 (95% CI = 0.98–0.78), respectively.
3.3. Comparison between Diagnostic Groups
In concordance with the high intrasubject reproducibility of the measurements, comparison between groups of participants followed the same pattern in the four blood samples collected on different days (BS1 to BS4), although some values varied slightly from one BS to another. Check Table 2 is based on the measurements of BS4.
The first striking result was that the concentration of UP Aβ1-40 and UP Aβ1-42 represented only approximately 1/3 and 1/4 of the levels in DP for any diagnostic group, respectively (Table 2). Second, the CB peptide levels, which were directly measured from the cellular fraction of the blood sample, were similar to the levels measured in the DP. Moreover, levels of Aβ1-40 and Aβ1-42 strongly correlated when measured in either UP, DP or CB (, 0.71 and 0.71, resp ). Significant correlations were also found between any pair of the six markers directly assayed in the samples (Aβ1-40 and Aβ1-42 in UP, PD, CB; Table 3).
Furthermore, we found that levels of every marker increased in MCI and AD patients compared to the healthy control group (Figure 1, Table 2). These increases reached statistical significance between the MCI and HC groups for the three Aβ1-40 markers (UP, DP, and CB which increased 2.9, 2.2 and 1.8 times resp.) and for the two Aβ1-42 plasma markers (UP and DP which increased 3.1 and 1.8 times resp.). The average level of every marker in the AD group was very similar to its average level in the MCI group and no significant differences were found between these two groups of patients.
Both Aβ1-40 and Aβ1-42 plasma markers (UP and DP), but not CB, correlated significantly with MMSE (Table 3), although it could be overestimated in part because of the clustering of HC toward the higher MMSE scores. In fact, when participants with MMSE ≥ 26 were excluded, levels of Aβ1-40 and Aβ1-42 were lower in severely affected patients (MMSE ≤ 21, ) than in moderately affected patients (MMSE 22–25, ), although the differences did not reach statistical significance (data not shown). Additionally, the levels of Aβ1-42 in UP and DP were found to significantly correlate with the degree of MTA in both the right and the left hemispheres (Table 3).
We also considered several markers that were calculated from those assayed directly from the samples. Apart from the usual Aβ1-42/Aβ1-40 ratios, the most interesting were the sum of DP plus CB Aβ1-40 and the sum of DP plus CB Aβ1-42, which we defined as total Aβ1-40 (T40) and total Aβ1-42 (T42), respectively; and the sum of these two, which we labeled total β-amyloid pool in blood (T-βAPB). The Aβ1-42/Aβ1-40 ratios, measured in UP, DP or CB, did not show significant differences between groups. However, the T40, T42 and T-βAPB increased 2.0, 1.5 and 1.8 times, respectively in the MCI group compared to the healthy control group () (Table 2). Similar average increases were found between HC and AD patients but in this case only T42 reach statistical significance (Figure 1).
3.4. Sensitivity and Specificity of the Direct and Calculated Markers
ROC curve analysis was used to assess the sensitivity and specificity of each marker (Table 4). Most direct markers and two calculated markers (T40 and T-βAPB) met the criteria considered suitable to distinguish between MCI patients and HC. Thus, all the Aβ1-40 markers, and UP Aβ1-42, presented an area under the ROC curve ≥ 0.80. The calculated T40 and T-βAPB were equally as accurate as the direct markers in distinguishing between MCI and HC, whereas T42 reached lower specificity (Table 4). Due to the great variability of Aβ measurements from one individual to another within the AD group, no critical point could be found at which these markers differentiated the AD patients from the other two groups of participants with an acceptable sensitivity and specificity (Figure 2).
Quantifying Aβ peptide levels in blood by ELISA is no doubt a demanding laboratory task; it requires considerable expertise due to a variety of technical reasons that compromise obtaining reliable and reproducible results. Demanding conditions of the assays and complexity of the procedures are mostly related to the relative low levels of these peptides in the blood and their high hydrophobic nature [11, 31, 32]. Due to the low levels of Aβ peptides in blood, it is critical to use antibodies with high affinity and to strictly standardize the methodology for the Aβ blood test, as has been done for CSF test in the framework of the Alzheimer Disease Neuroimaging Initiative (ADNI) (http://www.adni-info.org/) and other projects (http://www.neurochem.gu.se/theAlzAssQCProgram) from sample collection to final assay . Our results show that if sufficient attention is devoted to these issues, the ELISA sandwich colorimetric test is sensitive enough to detect low concentrations of Aβ (LLD < 6 pg/mL) with very good intra-assay repeatability and interlaboratory reproducibility, even with a relatively low number of samples.
The biochemical properties of Aβ peptides make them very difficult molecules to work with due to their tendency to self-aggregate and to develop hydrophobic interactions with any other molecules in their vicinity. In the present work, we systematically analyzed, for the first time, the levels of Aβ peptides in UP, DP, and CB. We hypothesized that the levels of Aβ peptides measured in UP could correspond mainly to the amount of peptides free in the plasma. Dilution of the plasma with sample buffer changed the ionic strength and molecular interactions within the sample, leading to the release of Aβ1-40 and Aβ1-42 bound to plasma protein and other components [31, 34]. Thus, the increase in the measurements after dilution of the plasma might be due to the detection of Aβ peptides released from proteins and other plasma components and could be interpreted as an estimation of the total level of Aβ in plasma [6, 23, 25]. Theoretically, the possibility that the breakage of Aβ oligomers present in plasma might contribute to this increase could not be excluded and will be the object of future research [19, 20]. Further, we found that around 50% of the total βAPB was bound to the cellular pellet remaining after centrifugation, a fraction usually not considered for Aβ quantification. This finding is consistent with previous reports of Aβ peptides bound to erythrocytes by complement receptor C1, which mediates a significant proportion of Aβ clearance from the bloodstream . In any case, these results show that Aβ peptide levels in blood could be much higher than the levels usually reflected by most ELISAs which do not take into account the substantial amounts of peptides bound to plasma proteins and blood cells. From a practical point of view, this might not be a major problem since in the present study, levels of Aβ1-42 free in the plasma reached by themselves a sensitivity and specificity enough to distinguish between MCI and HC. However, it should be considered that UP Aβ1-42 levels, particularly in healthy controls are very low, close to the LLD of most ELISA kits, which many times impairs the reliability of these measurements. Our results suggest that other more substantial and reliable markers as DP and CB Aβ1-40 and even DP Aβ1-42 could enable also a suitable differentiation between HC and MCI patients. Thus, a complete determination of the total βAPB blood levels should include the quantification of the peptides that are free in plasma, bound to plasma proteins and bound to blood cells. This comprehensive quantification of the different components of the βAPB would give a more precise measurement of Aβ blood levels and might help to ascertain the complex regulation of Aβ peptides in health and disease.
Mounting evidence is reinforcing the idea that Aβ blood levels are affected in MCI and AD patients, although controversy remains based on some contradictory reports. In the present work, samples from MCI or AD participants, when compared to HC, showed a considerable increase in the detection of six directly assayed βAPB markers. For five of these six markers, the increases were statistically significant between HC and MCI, but not between AD and HC. Nevertheless, caution should be exerted interpreting these results since comparisons were not adjusted for age. It should be taken into account that adjustment for age might be by itself a confounding factor in transversal studies fading possible differences between healthy controls and MCI patients. Age is the main risk factor for AD and experimental results are increasingly supporting that beta-amyloid modifications, detected either by PET-PIB or CSF ELISA assay, are the earliest sings of AD amyloid pathology which could be in place many years before the first cognitive symptom could be detected. Furthermore, it is believed that Aβ levels reach a kind of plateau and do not keep increasing as disease progress . Thus in transversal studies, increasing the age of the participant (or statistically adjusting the weight of the younger controls) would increase the possibility of misplacing patients with cognitively-asymptomatic-AD amyloid pathology within the “healthy control” groups (or increasing their statistical weight), which might fade the presumptive differences in Aβ markers between “healthy control” and MCI patients.
The present results are consistent with numerous studies on late-onset AD that reported a relationship between elevated plasma Aβ peptide levels and disease [15, 16, 18–21, 32, 36–38]. It is becoming clear from these studies that increases in Aβ blood levels is an early event that precedes the onset of cognitive symptoms and increases the risk of developing AD. Studies with MRI and PET-PIB also support the idea that an individual’s amyloid load accumulates prior to clinical symptoms and reaches a plateau with no further or very slow accumulation as the disease progresses clinically . This idea is also supported by experimental results from early-onset familial AD and Downs syndrome patients who develop dementia of the Alzheimer type and from studies in transgenic mouse models of the disease [14, 17]. Interestingly, several studies report significant decreases in Aβ blood levels (again more marked for Aβ1-42 than for Aβ1-40) as the disease progresses [15, 16, 19–21]. Our results also suggest that when MCI can be clinically detected, the different markers of the βAPB tend to stabilize at levels higher than normal on average and then tend to decrease in patients with lower MMSE.
Lack of significance between our AD and HC groups is most likely due to the large range of measurements in the AD group, in which levels of the different markers varied considerably from one individual to another (2.5 to 5.7 times the coefficient of variation observed in the HC). In fact, our results showed a clear increase in the coefficient of variation of the different markers as the disease progresses from HC to MCI and AD groups (Table 2). This variability of Aβ blood levels within the AD group might reflect an actual characteristic of the disease and could be related to individual features like the presence of other systemic or neurological pathologies, including the affectation of cerebral blood vessels and blood brain barrier, which frequently accompany AD [21, 40]. Reports on increases in Aβ blood levels in early stages of AD have been sometimes interpreted as contradictory to the well defined CSF biomarker signature of AD, which demonstrates a significant decrease in Aβ1-42 [4, 6]. In our opinion, this discrepancy could have been misinterpreted and could be likely related to a different temporal sequence of changes in Aβ peptide levels in blood compared to CSF. Thus, Aβ produced by cortical neurons has to travel a long distance through the interstitial fluid (ISF) to reach the ventricular system located deep within the brain, at least several millimeters away. During this travel along facilitated routes passing by fiber tracts and blood vessels, Aβ will have to cross a huge number of capillaries that thoroughly pierce brain tissue ~40 μm from each other . The amyloid hypothesis states that at the onset of AD pathology, Aβ peptides start to aggregate and precipitate in the interstitial space of the brain. In this situation, diffusion of Aβ in the ISF toward the ventricular system will be severely hampered, leading to a reduction of Aβ1-42 levels in CSF that herald cognitive decline. At this initial stage, without extensive capillary damage, the increased Aβ blood levels observed in the present work and previous reports might reflect the increased peptide levels in brain tissue. Nevertheless, as suggested by reports from longitudinal studies, Aβ blood levels would finally drop in most patients probably after the deposition of Aβ around capillaries would seal off the BBB. The fact that in the present pilot study, the levels of Aβ1-40 and Aβ1-42 in the most severely affected patients (MMSE ≤ 21, ) were lower than those in moderately affected patients (MMSE 22–25, ) is congruent with this interpretation. Further experiments are needed to understand the circulation of Aβ between ISF, CSF, and blood as well as the relationship between biochemical and neuroimaging biomarkers [35, 42–46].
Our results do not support previous studies that reported a lack of a relationship between Aβ plasma levels and risk of AD or an association between either low plasma Aβ levels or low Aβ1-42/Aβ1-40 ratio and AD [6, 47–51]. Interestingly, some of these studies were aimed at comparing healthy controls to overt AD patients or pooled MCI and AD patients within the same group [47–49]. These inconsistencies could most likely be accounted for by differences in the timing of sample collection with regard to the onset of the disease and the stage of progression.
It is still too early to clearly establish the role of the Aβ blood test as a diagnostic tool for MCI and AD. Nevertheless, in the present work we have shown that most direct markers of the βAPB and two calculated markers (T40 and the total βAPB) reported promising results to distinguish between MCI patients and HC. This could be of utmost interest because from any practical point of view it is there were the diagnostic should be improved. However, the small sample size of this pilot study did not allow definitive conclusion on this regard but most markers of the βAPB showed consistent results that will be useful to adequately estimate the sample size for further statistically well-powered analysis of the diagnostic capabilities of these biomarkers.
In summary, the Aβ blood test should include the quantification of the peptides that are free in plasma, bound to plasma proteins and bound to blood cells. Provided there is a well-established standardization of the procedures, the ELISA test can produce reliable measurements with high repeatability, low limits of detection, and substantial inter-laboratory reproducibility. Under these conditions, the levels of several direct and calculated markers of the βAPB appear to be useful for the diagnosis of mild cognitive impairment and their quantification should be included in the ordinary analytical battery of tests on aged patients with memory complaints.
P. Pesini, V. Pérez. Grijalba, I. Monleón, I. San José and M. Sarasa are employees at Araclon Biotech. M. Boada is in the scientific advisory committee of Araclon Biotech. P. Martínez Lage. and L. T árraga have no actual or potential conflict of interest. This work has been partially financed by Spanish CDTI and ENISA.
- P. T. Nelson, H. Braak, and W. R. Markesbery, “Neuropathology and cognitive impairment in alzheimer disease: a complex but coherent relationship,” Journal of Neuropathology and Experimental Neurology, vol. 68, no. 1, pp. 1–14, 2009.
- L. M. Shaw, H. Vanderstichele, M. Knapik-Czajka et al., “Cerebrospinal fluid biomarker signature in alzheimer's disease neuroimaging initiative subjects,” Annals of Neurology, vol. 65, no. 4, pp. 403–413, 2009.
- O. Hansson, H. Zetterberg, P. Buchhave et al., “Prediction of Alzheimer's disease using the CSF Aβ42/Aβ40 ratio in patients with mild cognitive impairment,” Dementia and Geriatric Cognitive Disorders, vol. 23, no. 5, pp. 316–320, 2007.
- P. Lewczuk, J. Kornhuber, H. Vanderstichele et al., “Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study,” Neurobiology of Aging, vol. 29, no. 6, pp. 812–818, 2008.
- N. Mattsson, H. Zetterberg, O. Hansson et al., “CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment,” Journal of the American Medical Association, vol. 302, no. 4, pp. 385–393, 2009.
- O. Hansson, H. Zetterberg, E. Vanmechelen et al., “Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment,” Neurobiology of Aging, vol. 31, no. 3, pp. 357–367, 2010.
- M. Shibata, S. Yamada, S. Ram Kumar et al., “Clearance of Alzheimer's amyloid-β1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier,” Journal of Clinical Investigation, vol. 106, no. 12, pp. 1489–1499, 2000.
- R. E. Tanzi, R. D. Moir, and S. L. Wagner, “Clearance of Alzheimer's Aβ peptide: the many roads to perdition,” Neuron, vol. 43, no. 5, pp. 605–608, 2004.
- R. Deane, R. D. Bell, A. Sagare, and B. V. Zlokovic, “Clearance of amyloid-β peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease,” CNS and Neurological Disorders, vol. 8, no. 1, pp. 16–30, 2009.
- H. Zetterberg, “Is plasma amyloid-β a reliable biomarker for Alzheimer's disease?” Recent Patents on CNS Drug Discovery, vol. 3, no. 2, pp. 109–111, 2008.
- O. I. Okereke, W. Xia, M. C. Irizarry et al., “Performance characteristics of plasma amyloid-β 40 and 42 assays,” Journal of Alzheimer's Disease, vol. 16, no. 2, pp. 277–285, 2009.
- A. Cedazo-Minguez and B. Winblad, “Biomarkers for Alzheimer's disease and other forms of dementia: clinical needs, limitations and future aspects,” Experimental Gerontology, vol. 45, no. 1, pp. 5–14, 2010.
- N. Schupf, B. Patel, D. Pang et al., “Elevated plasma β-amyloid peptide Aβ42 levels, incident dementia, and mortality in Down syndrome,” Archives of Neurology, vol. 64, no. 7, pp. 1007–1013, 2007.
- D. Scheuner, C. Eckman, M. Jensen et al., “Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease,” Nature Medicine, vol. 2, no. 8, pp. 864–870, 1996.
- A. Assini, S. Cammarata, A. Vitali et al., “Plasma levels of amyloid β-protein 42 are increased in women with mild cognitive impairment,” Neurology, vol. 63, no. 5, pp. 828–831, 2004.
- R. Mayeux, L. S. Honig, M. X. Tang et al., “Plasma Aβ40 and Aβ42 and Alzheimer's disease: relation to age, mortality, and risk,” Neurology, vol. 61, no. 9, pp. 1185–1190, 2003.
- N. Ertekin-Taner, L. H. Younkin, D. M. Yager et al., “Plasma amyloid β protein is elevated in late-onset Alzheimer disease families,” Neurology, vol. 70, no. 8, pp. 596–606, 2008.
- I. Blasko, K. Jellinger, G. Kemmler et al., “Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine,” Neurobiology of Aging, vol. 29, no. 1, pp. 1–11, 2008.
- N. Schupf, M. X. Tang, H. Fukuyama et al., “Peripheral Aβ subspecies as risk biomarkers of Alzheimer's disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 37, pp. 14052–14057, 2008.
- W. Xia, T. Yang, G. Shankar et al., “A specific enzyme-linked immunosorbent assay for measuring β-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer Disease,” Archives of Neurology, vol. 66, no. 2, pp. 190–199, 2009.
- T. Sobów, M. Flirski, I. Kloszewska, and P. P. Liberski, “Plasma levels of Aβ peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease,” Acta Neurobiologiae Experimentalis, vol. 65, no. 2, pp. 117–124, 2005.
- T. Kawarabayashi, L. H. Younkin, T. C. Saido, M. Shoji, K. H. Ashe, and S. G. Younkin, “Age-dependent changes in brain, CSF, and plasma amyloid β protein in the Tg2576 transgenic mouse model of Alzheimer's disease,” Journal of Neuroscience, vol. 21, no. 2, pp. 372–381, 2001.
- A. L. Biere, B. Ostaszewski, E. R. Stimson, B. T. Hyman, J. E. Maggio, and D. J. Selkoe, “Amyloid β-peptide is transported on lipoproteins and albumin in human plasma,” Journal of Biological Chemistry, vol. 271, no. 51, pp. 32916–32922, 1996.
- J. Rogers, R. Li, D. Mastroeni et al., “Peripheral clearance of amyloid β peptide by complement C3-dependent adherence to erythrocytes,” Neurobiology of Aging, vol. 27, no. 12, pp. 1733–1739, 2006.
- E. Matsubara, Y. Sekijima, T. Tokuda et al., “Soluble Aβ homeostasis in AD and DS: impairment of anti-amyloidogenic protection by lipoproteins,” Neurobiology of Aging, vol. 25, no. 7, pp. 833–841, 2004.
- K. Blennow, H. Hampel, M. Weiner, and H. Zetterberg, “Cerebrospinal fluid and plasma biomarkers in Alzheimer disease,” Nature Reviews Neurology, vol. 6, no. 3, pp. 131–144, 2010.
- P. Scheltens, D. Leys, F. Barkhof et al., “Atrophy of medial temporal lobes on MRI in 'probable' Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates,” Journal of Neurology Neurosurgery and Psychiatry, vol. 55, no. 10, pp. 967–972, 1992.
- M. Alegret, M. Boada-Rovira, G. Vinyes-Junqué et al., “Detection of visuoperceptual deficits in preclinical and mild Alzheimer's disease,” Journal of Clinical and Experimental Neuropsychology, vol. 31, no. 7, pp. 860–867, 2009.
- J. E. Hixson and D. T. Vernier, “Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI,” Journal of Lipid Research, vol. 31, no. 3, pp. 545–548, 1990.
- H. X. Barnhart, M. Haber, and J. Song, “Overall concordance correlation coefficient for evaluating agreement among multiple observers,” Biometrics, vol. 58, no. 4, pp. 1020–1027, 2002.
- Y. M. Kuo, M. R. Emmerling, H. C. Lampert et al., “High levels of circulating Aβ42 are sequestered by plasma proteins in Alzheimer's disease,” Biochemical and Biophysical Research Communications, vol. 257, no. 3, pp. 787–791, 1999.
- P. D. Mehta, T. Pirttilä, S. P. Mehta, E. A. Sersen, P. S. Aisen, and H. M. Wisniewski, “Plasma and cerebrospinal fluid levels of amyloid β proteins 1-40 and 1- 42 in Alzheimer disease,” Archives of Neurology, vol. 57, no. 1, pp. 100–105, 2000.
- R. C. Petersen, P. S. Aisen, L. A. Beckett et al., “Alzheimer's disease neuroimaging initiative (ADNI): clinical characterization,” Neurology, vol. 74, no. 3, pp. 201–209, 2010.
- N. Sureshbabu, R. Kirubagaran, and R. Jayakumar, “Surfactant-induced conformational transition of amyloid β-peptide,” European Biophysics Journal, vol. 38, no. 4, pp. 355–367, 2009.
- P. Vemuri, H. J. Wiste, S. D. Weigand et al., “MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change,” Neurology, vol. 73, no. 4, pp. 294–301, 2009.
- O. L. Lopez, L. H. Kuller, P. D. Mehta et al., “Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study,” Neurology, vol. 70, no. 19, pp. 1664–1671, 2008.
- P. Szabo, N. Relkin, and M. E. Weksler, “Natural human antibodies to amyloid beta peptide,” Autoimmunity Reviews, vol. 7, no. 6, pp. 415–420, 2008.
- M. van Oijen, A. Hofman, H. D. Soares, P. J. Koudstaal, and M. M. Breteler, “Plasma Aβ1-40 and Aβ1-42 and the risk of dementia: a prospective case-cohort study,” Lancet Neurology, vol. 5, no. 8, pp. 655–660, 2006.
- C. R. Jack Jr, V. J. Lowe, S. D. Weigand et al., “Serial PIB and MRI in normal, mild cognitive impairment and Alzheimers disease: implications for sequence of pathological events in Alzheimers disease,” Brain, vol. 132, no. 5, pp. 1355–1365, 2009.
- V. Giedraitis, J. Sundelöf, M. C. Irizarry et al., “The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease,” Neuroscience Letters, vol. 427, no. 3, pp. 127–131, 2007.
- B. V. Zlokovic, “Neurovascular mechanisms of Alzheimer's neurodegeneration,” Trends in Neurosciences, vol. 28, no. 4, pp. 202–208, 2005.
- A. M. Fagan, D. Head, A. R. Shah et al., “Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderly,” Annals of Neurology, vol. 65, no. 2, pp. 176–183, 2009.
- P. Vemuri, H. J. Wiste, S. D. Weigand et al., “MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations,” Neurology, vol. 73, no. 4, pp. 287–293, 2009.
- G. B. Frisoni, N. C. Fox, C. R. Jack Jr, P. Scheltens, and P. M. Thompson, “The clinical use of structural MRI in Alzheimer disease,” Nature Reviews Neurology, vol. 6, no. 2, pp. 67–77, 2010.
- W. J. Jagust, S. M. Landau, L. M. Shaw et al., “Relationships between biomarkers in aging and dementia,” Neurology, vol. 73, no. 15, pp. 1193–1199, 2009.
- H. Hampel, K. Bürger, S. J. Teipel, A. L. W. Bokde, H. Zetterberg, and K. Blennow, “Core candidate neurochemical and imaging biomarkers of Alzheimer's disease**This paper was presented in part by the 1st author at the 10th International Conference of Alzheimer's Disease and Related Disorders (ICAD), Madrid, Spain, July 2006, as an invited plenary lecture,” Alzheimer's and Dementia, vol. 4, no. 1, pp. 38–48, 2008.
- N. R. Graff-Radford, J. E. Crook, J. Lucas et al., “Association of low plasma Aβ42/Aβ40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease,” Archives of Neurology, vol. 64, no. 3, pp. 354–362, 2007.
- S. H. Freeman, S. Raju, B. T. Hyman, M. P. Frosch, and M. C. Irizarry, “Plasma Aβ levels do not reflect brain Aβ levels,” Journal of Neuropathology and Experimental Neurology, vol. 66, no. 4, pp. 264–271, 2007.
- J. Sundelof, V. Giedraitis, M. C. Irizarry et al., “Plasma β amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study,” Archives of Neurology, vol. 65, no. 2, pp. 256–263, 2008.
- P. Lewczuk, J. Kornhuber, E. Vanmechelen et al., “Amyloid β peptides in plasma in early diagnosis of Alzheimer's disease: a multicenter study with multiplexing,” Experimental Neurology, vol. 223, no. 2, pp. 366–370, 2010.
- J. C. Lambert, S. Schraen-Maschke, F. Richard et al., “Association of plasma amyloid β with risk of dementia: the prospective Three-City Study,” Neurology, vol. 73, no. 11, pp. 847–853, 2009.